Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

New canine oral cancer drug to be trialled
Owners of dogs with oral melanoma are being encouraged to participate in the trial.
The drug is already licensed to another form of canine cancer.

A pilot trial is set to be carried out to test the ability of a drug derived from berries to treat canine oral melanoma.

Researchers at the Royal (Dick) School of Veterinary Studies in Edinburgh, Scotland will assess the effectiveness of the drug tigilanol tiglate, which is derived from the berries of the blushwood tree, a species found in Queensland, Australia.

The drug, which disrupts blood vessels inside tumours without harming healthy tissue, is currently licensed to treat mast cell tumours. If it is shown to work to treat canine oral melanoma, it may save some dogs from having to undergo surgery.

The researchers hope that the trial could also provide insights that could benefit human medicine, as canine oral melanoma shares many features with human mucosal melanoma. In both diseases, symptoms typically remain hidden until the disease has already reached an advanced stage.

The research is being funded by QBiotics, the manufacturer of tigilanol tiglate, which it sells under the brand name Stelfonta.

The trial will involve eight dogs, although the number of participating animals may be increased if the initial results prove to be promising. Owners of eligible dogs are being asked to get in touch with the research team.

Kelly Blacklock, professor of small animal soft tissue surgery, said: “If successful, this treatment could transform the way we approach cancer therapy in veterinary medicine, sparing many dogs from the need for surgery.

“We encourage pet owners with dogs diagnosed with oral melanoma to consider participating in this trial. Your involvement could not only contribute to advancing treatment options for this challenging disease but also help improve the quality of life for dogs in the future.”

Eligible dog owners wishing to take part should email Professor Blacklock.

Image © Shutterstock

Become a member or log in to add this story to your CPD history

Vets launch new podcast for pet owners

News Story 1
 Two independent vets have launched a podcast to help owners strengthen their bond with pets. Dr Maggie Roberts and Dr Vanessa Howie, who have worked in both veterinary practice and major charities, are keen to use their experience to enable people to give pets a better life.

The venture, called Vets Talking Pets, provides advice and information on a range of topics, including how to select a suitable pet, where to obtain them and how to get the best out of your vet. Maggie and Vanessa will also discuss sensitive subjects, including end-of-life care, raw food diets and the cost of veterinary care.

The podcast can be found on all the usual podcast sites, including Podbean, Apple, Amazon Music and YouTube. 

Click here for more...
News Shorts
VMD issues guidance on AVM-GSL packaging

The Veterinary Medicines Directorate (VMD) has shared advice on its requirements for medicines considered AVM-GSL.

The guidance explains the information that should be on the outer package, and sets out the typical maximum pack size for an AVM-GSL product. It also describes the user-friendly language, structure and phrases required on packaging and product leaflets.

AVM-GSL products do not require discussion between the purchaser and a veterinary professional. This means that clear product information is needed to support sales choices.

The information will be useful for submitting new products to the AVM-GSL category and lowering the distribution category of products from NFA-VPS to AVM-GSL.

The VMD's guidance can be accessed here.